Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ACTengine® IMA203CD8 GEN2 (PRAME) in Metastatic melanoma. The expected timing is based on the latest available company guidance and may change.
11/8/23- First clinical data from Cohort C. 10/10/24- Updated positive Ph1b data. 11/8/24- Oral presentation at SITC 2024. 4/23/25- Updated Ph1b data presented at ASCO '25. 11/17/25:- Next Ph1a dose escalation data for IMA203CD8 at ESMO IO on December 11, 2025. 12/11/25:- Ph1a dose escalation data presented; plan to complete dose escalation and define RP2D in 2026. 03/05/26:- Ph1a data focused on ovarian cancer planned at major conference H1 2026; Ph1a dose escalation/RP2D completion remains 2026. 04/21/26:- IMA203CD8 ovarian cancer results at ASCO; abstracts May 21, 2026; oral May 30. 05/12/26:- Phase 1 data readout for IMA203CD8 in gynecologic cancers at ASCO 2026; program pursuing tumor-agnostic expansion across advanced PRAME cancers. 05/30/26:- IMA203CD8 activity reiterated across tumor types incl melanoma. Updated NCT03686124 follow-up at RP2D planned H2 2026. 07/17/26:- ESMO 2026 Phase 1 IMA203CD8 results abstract Oct 19; oral Oct 23, 2026. 08/18/26:- Phase 1 dose escalation was completed. Updated multi-tumor data will be presented at ESMO 2026.
Verification
Confirm timing and program details against the company announcement or filing.